Laurent Martarello

Biogen (United States) — United States

Medicine · Health Sciences

28h-index2.0kcitations111works5.72yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Medical Imaging Techniques and Applications(24), Glycosylation and Glycoproteins Research(21), Angiogenesis and VEGF in Cancer(20), Galectins and Cancer Biology(16), Neuroscience and Neuropharmacology Research(14)

Publications109 total

Central Nervous System Biodistribution and Pharmacokinetics of Radiolabeled Tofersen in Rodents, Nonhuman Primates, and Humans
Journal of Nuclear Medicine·2025Open Access
PET imaging of antisense oligonucleotide distribution in rat and nonhuman primate brains using click chemistry
Science Translational Medicine·2025· 7 cited
In vivo quantification of [ <sup>11</sup> C]BIO-1819578 in non-human primates, a novel radioligand for O-GlcNAcase
Journal of Cerebral Blood Flow & Metabolism·2025Open Access
PET imaging of an antisense oligonucleotide in the living non-human primate brain using click chemistry
2025
Labeling of Bruton’s Tyrosine Kinase (BTK) Inhibitor [11C]BIO-2008846 in Three Different Positions and Measurement in NHP Using PET
International Journal of Molecular Sciences·2024Open Access
Cinpanemab in Early Parkinson Disease
Neurology·2024· 27 citedOpen Access
Discovery of [18F]F-687-TCO: An Optimized Tracer for Pretargeted PET Imaging in the CNS
Nuclear Medicine and Biology·2023· 1 cited
Exploratory Tau Biomarker Results From a Multiple Ascending-Dose Study of BIIB080 in Alzheimer Disease
JAMA Neurology·2023· 79 citedOpen Access
Development of a PET Tracer for OGA with Improved Kinetics in the Living Brain
Journal of Nuclear Medicine·2023· 11 citedOpen Access
Development of a Novel [<sup>11</sup>C]CO-Labeled Positron Emission Tomography Radioligand [<sup>11</sup>C]BIO-1819578 for the Detection of <i>O</i>-GlcNAcase Enzyme Activity
ACS Chemical Neuroscience·2023· 7 citedOpen Access
Supplementary Figure 2 from Ang-2-VEGF-A CrossMab, a Novel Bispecific Human IgG1 Antibody Blocking VEGF-A and Ang-2 Functions Simultaneously, Mediates Potent Antitumor, Antiangiogenic, and Antimetastatic Efficacy
2023Open Access
Supplementary Figure 3 from Ang-2-VEGF-A CrossMab, a Novel Bispecific Human IgG1 Antibody Blocking VEGF-A and Ang-2 Functions Simultaneously, Mediates Potent Antitumor, Antiangiogenic, and Antimetastatic Efficacy
2023Open Access
Supplementary Table 1 from Ang-2-VEGF-A CrossMab, a Novel Bispecific Human IgG1 Antibody Blocking VEGF-A and Ang-2 Functions Simultaneously, Mediates Potent Antitumor, Antiangiogenic, and Antimetastatic Efficacy
2023Open Access
Supplementary Figure 1 from Ang-2-VEGF-A CrossMab, a Novel Bispecific Human IgG1 Antibody Blocking VEGF-A and Ang-2 Functions Simultaneously, Mediates Potent Antitumor, Antiangiogenic, and Antimetastatic Efficacy
2023Open Access
Data from Ang-2-VEGF-A CrossMab, a Novel Bispecific Human IgG1 Antibody Blocking VEGF-A and Ang-2 Functions Simultaneously, Mediates Potent Antitumor, Antiangiogenic, and Antimetastatic Efficacy
2023· 1 citedOpen Access
Supplementary Figure 7 from Ang-2-VEGF-A CrossMab, a Novel Bispecific Human IgG1 Antibody Blocking VEGF-A and Ang-2 Functions Simultaneously, Mediates Potent Antitumor, Antiangiogenic, and Antimetastatic Efficacy
2023Open Access
Supplementary Figure 5 from Ang-2-VEGF-A CrossMab, a Novel Bispecific Human IgG1 Antibody Blocking VEGF-A and Ang-2 Functions Simultaneously, Mediates Potent Antitumor, Antiangiogenic, and Antimetastatic Efficacy
2023Open Access
Supplementary Figure 4 from Ang-2-VEGF-A CrossMab, a Novel Bispecific Human IgG1 Antibody Blocking VEGF-A and Ang-2 Functions Simultaneously, Mediates Potent Antitumor, Antiangiogenic, and Antimetastatic Efficacy
2023Open Access
Supplementary Material from Ang-2-VEGF-A CrossMab, a Novel Bispecific Human IgG1 Antibody Blocking VEGF-A and Ang-2 Functions Simultaneously, Mediates Potent Antitumor, Antiangiogenic, and Antimetastatic Efficacy
2023Open Access
Supplementary Material from Ang-2-VEGF-A CrossMab, a Novel Bispecific Human IgG1 Antibody Blocking VEGF-A and Ang-2 Functions Simultaneously, Mediates Potent Antitumor, Antiangiogenic, and Antimetastatic Efficacy
2023Open Access
page 1 of 6Next →

Frequent Co-authors

Mark M. Goodman(12), Antony D. Gee(12), Roger N. Gunn(10), Robert A. Comley(9), Eugenii A. Rabiner(8), Christophe Plisson(8), John R. Votaw(7), Christine A. Parker(7), Vincent J. Cunningham(7), Vernon M. Camp(6), Eugene Malveaux(5), Marc Laruelle(5), Clinton D. Kilts(4), John D. Beaver(4), Gilbert Kirsch(4), Jonathan McConathy(4), Cristian Salinas(4), Graham E. Searle(4), Tong San Koh(4), Septian Hartono(4)